A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia

Trial ID or NCT#

NCT04320615

Status

not recruiting iconNOT RECRUITING

Purpose

This study will evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics of tocilizumab (TCZ) compared with a matching placebo in combination with standard of care (SOC) in hospitalized patients with severe COVID-19 pneumonia.

Official Title

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia

Eligibility Criteria

Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Nidhi Rohatgi, MD MS
Nidhi Rohatgi, MD MS
Hospitalist
Clinical Professor, Medicine Clinical Professor (By courtesy), Neurosurgery Clinical Professor (By courtesy), Anesthesiology, Perioperative and Pain Medicine
Andre Kumar MD, MEd
Hospitalist
Clinical Professor, Medicine

View on ClinicalTrials.gov